Clinical Operations: Biggest Challenges Facing the Industry in 2020
I’m often asked, by clients across the globe, what the main Clinical Operations challenges facing pharma and biotech companies really are. Where are they investing their resources? What takes up their time? Where are their efforts going to be focused...
5 years agoClinical Operations: Biggest Challenges Facing the Industry in 2020
I’m often asked, by clients across the globe, what the main Clinical Operations challenges facing pharma and biotech companies really are. Where are they investing their resources? What takes up their time? Where are their efforts going to be focused...
5 years ago
The Changing Role of the Blockbuster Drug
There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...
5 years agoThe Changing Role of the Blockbuster Drug
There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...
5 years ago
Trending Innovations in Cold Chain Processes
As is increasingly known in the pharmaceutical industry, the rise in both trial costs and drug failures has seen a corresponding increase in the need for tight regulations and stricter procedures, to ensure the few successes are not further compromised....
5 years agoTrending Innovations in Cold Chain Processes
As is increasingly known in the pharmaceutical industry, the rise in both trial costs and drug failures has seen a corresponding increase in the need for tight regulations and stricter procedures, to ensure the few successes are not further compromised....
5 years ago
How Can We Speed up Vaccine R&D?
With the rapid spread of the coronavirus 2019-nCoV through China and now globally, governments and organisations have implemented a range of preventative measures. Chinese provinces including Beijing and Shanghai have shut down long-distance bus services and entirely closed off some...
5 years agoHow Can We Speed up Vaccine R&D?
With the rapid spread of the coronavirus 2019-nCoV through China and now globally, governments and organisations have implemented a range of preventative measures. Chinese provinces including Beijing and Shanghai have shut down long-distance bus services and entirely closed off some...
5 years ago
Weekly News Round-up – 24/1/20
The World Health Organisation (WHO) has been in the news a lot this week, a fact that doesn't often herald good news. The first, of course, was to discuss the outbreak of a new coronavirus in China, against which no antidote...
5 years agoWeekly News Round-up – 24/1/20
The World Health Organisation (WHO) has been in the news a lot this week, a fact that doesn't often herald good news. The first, of course, was to discuss the outbreak of a new coronavirus in China, against which no antidote...
5 years ago
Avoiding Bias in Precision Medicine
Precision medicine, or the tailoring of healthcare towards either a select group or individual based on their needs and physiology instead of their illness, is a well-known and highly-anticipated aspect of healthcare pharmaceuticals, with thousands of articles written on it. ...
5 years agoAvoiding Bias in Precision Medicine
Precision medicine, or the tailoring of healthcare towards either a select group or individual based on their needs and physiology instead of their illness, is a well-known and highly-anticipated aspect of healthcare pharmaceuticals, with thousands of articles written on it. ...
5 years ago
The Future of Organ-on-a-Chip
Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....
5 years agoThe Future of Organ-on-a-Chip
Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....
5 years ago
Time to invest in CGT: Its Benefits for Pharma
The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...
5 years agoTime to invest in CGT: Its Benefits for Pharma
The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...
5 years ago
Single-Use Technologies: Challenges and Solutions
Since their increased popularisation from the mid-1990s, single- and limited-use technologies (collectively SUTs) have changed the field of biomanufacturing. This has been driven partly by the heavy growth of the pharma market, from $162 billion in 2014 to around $270...
5 years agoSingle-Use Technologies: Challenges and Solutions
Since their increased popularisation from the mid-1990s, single- and limited-use technologies (collectively SUTs) have changed the field of biomanufacturing. This has been driven partly by the heavy growth of the pharma market, from $162 billion in 2014 to around $270...
5 years ago
The Abbvie-Allergan Deal: A Matter of Distrust?
Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...
5 years agoThe Abbvie-Allergan Deal: A Matter of Distrust?
Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...
5 years ago